• The new revenue recognition standard - life sciences

    Due to the revenue recognition standards recently issued, life sciences entities may need to make changes. We highlight the key considerations and next steps.

  • Beyond borders: unlocking value

    With double-digit revenue growth and a sharp rise in funds raised, the global biotechnology industry rebounded strongly this year. Find out more in our annual report.

  • Life sciences: preparing for big data and analytics

    Many life sciences organizations are not capturing and applying value from analytics in a meaningful way. Gain the edge by harnessing today’s big data insights.

  • Navigating the payer landscape in pharma

    A revolution is happening in health care, and it’s being led by payers. Progressions, our global pharmaceutical report, explores how companies are responding.

  • Swiss Biotech Report 2014

    EY was significantly involved in producing the report. It highlights progress and change in the sector and gives insights into a broad range of topics.

  • Commercial excellence in pharma 3.0

    The pharmaceutical industry is navigating a profound transformation into what we call “Pharma 3.0.” We explore how companies are adapting their commercial models in response.

  • Firepower and Growth Gap Report 2014

    Big pharma needs mergers and acquisitions to grow, but the deal landscape is more competitive than ever. Read more about pharma's growth gap in our report.

  • 10 things to know about the 2013 IPO class

    Read our latest blog post, where Glen Giovannetti and colleagues tell the story of the 2013 US biotech IPO class in a 10-chart infographic.

  • Beyond Borders: global biotech report 2013

    We saw a strong performance by major biotech players, but a challenging environment for the rest of the industry. Read more in our 2013 industry report

Life Sciences

Finding sustainability in biotechnology, pharmaceutical and medical technology

Amplified business decisions are the new norm in today’s environment of rapid change in health care.

The life sciences community must explore a new course to address the changing climate — one driven by patients and focused on health outcomes.

From new market entrants and regulatory reform to expiring patents and rising prevalence of chronic disease, there are a myriad of hurdles to overcome.

Our Global Life Sciences Center brings together a worldwide team of professionals to help you achieve your potential.

We cover key issues in these areas:


  • Biotechnology

    More than any other technology, biotechnology has the potential to alter our lives in a positive way. And by achieving this potential, today’s biotech companies are delivering new levels of health, prosperity and sustainability — around the world.

    But with uncertain capital markets, increasing regulation, growing pricing pressures, and fierce competition in M&A, this sector faces numerous challenges.

    We have been a pioneering presence in the biotechnology industry for many years. As the first professional services firm to build a practice dedicated to serving your industry, it’s not surprising that we serve more biotech companies than any other professional services firm — by a wide margin.

    We remain committed to your business, sharing our deep knowledge in leading reports and through our network of knowledgeable professionals.

    Related content:

     

  • Pharmaceutical

    Pharmaceutical companies are facing great changes to the industry — emerging science, new products and services, shifting demographics, evolving regulations, transforming business models and increased stakeholder expectations. We are helping pharmaceutical companies around the globe to address the challenges presented by this new world we call Pharma 3.0.

    Pharma 3.0 stands for the next big wave of improvements in health care – driven not just by new products, but by behavioral change. The future priority will be to identify interventions that are most promising, and then realign the behavior of all stakeholders — patients, providers and manufacturers — around these interventions.

    We also publish a series of reports to bring you clear insights into assurance, tax, transaction, and other issues, as well as our annual report on pharmaceutical industry trends, Progressions.

    Our thought leadership helps you navigate the shifting global landscape and grow your business — the new business imperative of improving health outcomes.

    Related content:

  • Medical technology

    Fundamental drivers — from aging populations and increasingly prevalent chronic diseases to expanding needs for lifestyle medical procedures — suggest demand for medical technology products should be robust for years to come.

    Still, the road ahead is littered with risks and challenges. Within an industry that requires constant innovation, you’re under pressure to demonstrate value for the products you develop, comply with increased regulations and satisfy the demanding new consumer-turned-competitor.

    Not only are we the firm of choice for medtechs entering the public markets, we also audit more medtech companies that are tracked by the Russell 3000 and Standard & Poor’s than any other professional services firm.

    From venture funding and IPOs to initial product launches and global expansions, we have the proven experience to help medical technology organizations navigate every critical stage of their business life cycle.

    Related content:



Connect with us

Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.

EY Progressions: Navigating the payer landscape

Progressions - Navigating the payer landscape

A revolution is happening in health care, and it’s being led by payers. Progressions, our global pharmaceutical report, explores how companies are responding.